Selling by month
Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.
Disclosed planOne dollar scale for every month; the tallest bar is labeled
Pattern
What the filings show, past 12 months. Nothing here rates or predicts.
- Sold in 4 of the 13 calendar months from Oct 2025 to Oct 2026: Nov 2025, Mar 2026, Jun 2026 and Sep 2026.
- Largest single sale: $4.2M (109,031 shares) of Dianthus Therapeutics, Inc. on Nov 14, 2025. Filing
- No sale on record before this period.
Roles from filings
Every company we track where this person has filed, newest filing first.
| Company | Title | First filing | Latest filing |
|---|---|---|---|
| Dianthus Therapeutics, Inc. (DNTH) | EVP, Head of R&D | Sep 13, 2023 | Sep 3, 2026 |
Recent filings
The last 5 days with transactions, newest first, one line per trade date. Each number links to an SEC filing.
- Sep 1, 2026, Dianthus Therapeutics, Inc.: sold 23,124 shares for $2.5M, under a disclosed plan; 23,124 shares acquired by exercising options. 1 filing: 1
- Jun 1, 2026, Dianthus Therapeutics, Inc.: sold 26,530 shares for $2.4M, under a disclosed plan; 26,530 shares acquired by exercising options. 1 filing: 1
- Mar 12, 2026, Dianthus Therapeutics, Inc.: sold 33,830 shares for $2.8M, under a disclosed plan; 33,830 shares acquired by exercising options. 1 filing: 1
- Nov 14, 2025, Dianthus Therapeutics, Inc.: sold 109,031 shares for $4.2M, under a disclosed plan; 109,031 shares acquired by exercising options. 1 filing: 1
- Nov 13, 2025, Dianthus Therapeutics, Inc.: sold 87,507 shares for $3.2M, under a disclosed plan; 87,507 shares acquired by exercising options. 1 filing: 1
This page shows only what this person reported on SEC ownership filings. See the methodology. Spotted something wrong? Report an error.